Did you know that the Investment Office invests in new technology that has been “born” right here on campus?
The MINTS program was established in December 2011, and participates in direct investments in companies with technology developed at and licensed from the University. The primary goal of the MINTS initiative is to leverage the University’s Office of Technology Transfer’s existing commercialization efforts for investment purposes by making direct investments in University of Michigan startups from the University’s Long Term Portfolio’s venture capital allocation. Rafael Castilla, Director of Investments and Structuring and Felicia David-Visser, Sr. Manager of Investments have overseen the program since it was established.
Since its inception, the MINTS program had invested in sixteen life sciences and seven physical sciences companies. As of December 31, 2017, MINTS had invested close to $24 million and had 22 active companies; 10 of which are based in Michigan and employ more than 100 people with a goal of growing further into larger, successful companies.
The graph below shows the many different sectors that MINTS had invested in.
Below are a few examples of the companies that MINTS invests in locally:
|Fusion Coolant Systems, Inc., founded in 2011 and headquartered in Detroit, MI, delivers the next-generation of coolant and lubricant technology to advanced manufacturing operations through the use of supercritical carbon dioxide.|
|Histosonics, Inc., founded in 2009 and headquartered in Ann Arbor, MI, is developing a histotripsy platform that will fundamentally change the nature of surgery. Histotripsy uses the mechanical (non-thermal) properties of focused ultrasound to precisely destroy targeted tissues without damaging surrounding tissue or structures.|
|Movellus Circuits, Inc., founded in 2014, and headquartered in Ann Arbor, MI offers analog solutions with the flexibility of complete digital designs. The company’s mixed-signal semiconductors provide software solutions to optimize system-on-chips (SoCs).|
|ONL Therapeutics, founded in 2006 and headquartered in Ann Arbor, MI, is a biopharmaceutical company focused on development of novel therapies for preserving sight in a range of retinal diseases.|